<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105772">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01758562</url>
  </required_header>
  <id_info>
    <org_study_id>Capo</org_study_id>
    <nct_id>NCT01758562</nct_id>
  </id_info>
  <brief_title>Caphosol® Versus State-of-the-art Mouthcare in Patients With Allogeneic Stem Cell Transplantation: a Randomized Controlled Study About the Efficacy of the Mouth Rinse Caphosol®</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled study about the efficacy of the mouth rinse Caphosol in patients with
      allogeneic stem cell transplantation. 85% of the patients receive a severe oral mucositis
      due to their treatment.

      70 patients will be randomized in the intervention (Caphosol) or in the standard
      (state-of-the-art) group. Primary endpoint is the duration of the mucositis, secondary
      endpoints are the occurence of oral mucositis measured with the WHO-scale and the occurence
      of pain measured with the NRS-scale (Numeric Rating Scale).

        -  Trial with medical device
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Duration of oral mucositis</measure>
    <time_frame>20-30 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Allogeneic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>State-of-the-art mouth care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mouth rinse Caphosol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mouth rinse,aqueous solution. Caphosol is a preparation comprising two separately packaged aqueous solutions, a phosphate solution and a calcium solution, which, when both solutions are combined in equal volumes, forms a solution supersaturated with respect to both calcium and phosphate ions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Caphosol</intervention_name>
    <arm_group_label>Mouth rinse Caphosol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Allogeneic stem cell transplantation

          -  Male and female patients age 18-80

          -  Signed informed consent after information

        Exclusion criteria:

          -  Contra-indications due to ethical reasons

          -  Unable to read or write

          -  Unable to speak or understand the german language

          -  Low-salt diet
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Spirig, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Centre of Clinical Nursing Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anja Katharina Kroener</last_name>
    <phone>+41 (0)44 255 11 11</phone>
    <email>anja.kroener@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rebecca Spirig, Prof MD</last_name>
    <email>rebecca.spirig@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich, Centre of Clinical Nursing Science</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 9, 2013</lastchanged_date>
  <firstreceived_date>December 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
